A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of iStatis Gonorrhea Antigen Test
30. Juni 2026 aktualisiert von: bioLytical Laboratories
A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of iStatis Gonorrhea Antigen Test by Trained Personnel at Near-Patient or Point-of-Care Settings
The objective of this study is to evaluate the performance, usability, and contrived result interpretation of iStatis Gonorrhea Antigen Test (iStatis Gonorrhea Test) in the intended near-patient or point-of-care setting by trained personnel.
Studienübersicht
Status
Rekrutierung
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The study is designed to evaluate iStatis Gonorrhea Test performance when used by trained personnel as follows:
- A method comparison will be performed to determine the diagnostic sensitivity and specificity of the iStatis Gonorrhea Test compared to a reference test that is an approved, current on-market Gonorrhea/Chlamydia combo assay, Cobas CT/NG.
- To evaluate the usability of iStatis Gonorrhea Test by means of assessing user experience via a questionnaire in combination with the success in performing the test. A minimum of 15 intended users to participate in the usability evaluation.
- To evaluate and document whether intended users (trained personnel), a minimum of 15 intended users across a minimum of three (3) sites, can successfully interpret contrived iStatis Gonorrhea Test results that include - strong positive, weak positive, negative and a range of invalid results.
Studientyp
Interventionell
Einschreibung (Geschätzt)
650
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Ana Subramanian
- Telefonnummer: 16042046784
- E-Mail: asubramanian@biolytical.com
Studieren Sie die Kontaktsicherung
- Name: Patrick Diaz
- Telefonnummer: 16042046784
- E-Mail: pdiaz@biolytical.com
Studienorte
-
-
Gauteng
-
Johannesburg, Gauteng, Südafrika, 2193
- Rekrutierung
- Epicentre Health Research (Johannesburg)
-
Kontakt:
- Cherie Cawood
- Telefonnummer: +42 082 065 2172
- E-Mail: cheriec@epicentre.org.za
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Südafrika, 3650
- Rekrutierung
- Epicentre Health Research
-
Kontakt:
- Cherie Cawood
- Telefonnummer: +27 31 880 2150
- E-Mail: cheriec@epicentre.org.za
-
-
Western Cape
-
Cape Town, Western Cape, Südafrika, 7925
- Rekrutierung
- Epicentre Health Research (Cape Town)
-
Kontakt:
- Cherie Cawood
- Telefonnummer: +27 21 201 1658
- E-Mail: cheriec@epicentre.org.za
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Ja
Beschreibung
Inclusion Criteria
- Age > 16 years
- Subject (or legally authorized representative) is willing to provide written informed consent before any study procedures
- Female gender
- Subject is able and willing to provide vaginal swab specimen for study procedures (3-4 swabs)
- Subject can complete the required testing on the allocated testing day
- Subject can speak, read, and write English
- Subject's demographic information, risk factors, and symptoms are available and can be recorded on case report forms
- Subject agrees to comply with study procedures and sample collection for both the investigational device and the reference method
- Subject is willing to participate in the study site's standard-of-care Gonorrhea counselling and testing program and receive standard-of-care test results, as required and applicable
Subject is indicated for sexually transmitted infection testing for one or more of the following reasons:
- At risk of Gonorrhea, such as recent unprotected intercourse, multiple or new partners within < 60 days, known exposure to an infected partner, or prior STI history
- Having signs and/or symptoms suggestive of Gonorrhea (e.g., urethral, vaginal, rectal, or pharyngeal discharge; dysuria; pelvic or lower-abdominal pain; sore throat; or rectal discomfort)
- Undergoing routine or opportunistic STI screening, including family-planning, antenatal, or sexual-health clinic visits
- Undergoing re-testing (test-of-cure) > 7 days after completion of Gonorrhea treatment and clinically stable
- Undergoing co-testing for other STIs where Gonorrhea testing is part of a broader diagnostic panel
Exclusion Criteria
- Subject 15 years of age or younger
- Male gender
- Female currently menstruating
- Subject is unable or unwilling to provide informed consent
- Subject is medically unstable or has psychiatric condition(s) that pose a risk or prevent study compliance
- Subject is unable to provide paired samples for reference testing
- Subject requires urgent antimicrobial treatment before specimen collection
- Subject received systemic or topical antibiotics active against Gonorrhea within the previous 7 days
- Subject used topical intravaginal or rectal antiseptics within 48 hours prior to study sampling
- Previously enrolled for the same infection episode
- Anatomical or clinical contraindication to study sampling (e.g., severe cervical pathology)
- Recent urogenital procedure (e.g., cystoscopy, lavage) < 72 hours before study sampling
- Subject belongs to a protected group excluded by local ethics (e.g., incarcerated persons), unless explicitly approved by the EC/IRB
- Any condition that, in the opinion of trained personnel or study staff, would make the participant unsuitable or unsafe for enrolment, interfere with completion of assessments, consent, or questionnaires, or bias study outcomes
- Subject is participating in another interventional clinical study within 30 days that could interfere with study results
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Screening
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: iStatis Gonorrhea Test Performance (Operator-collected swabs)
Operator-collected vaginal swabs will be tested on the iStatis Gonorrhea Test
|
Vaginal swabs are tested on the iStatis Gonorrhea Antigen Test
|
|
Experimental: iStatis Gonorrhea Test Performance (Self-collected swabs)
Self-collected vaginal swabs will be tested on the iStatis Gonorrhea Test.
Participants assigned to the self-collection arm of the study will complete the self-collection Usability Questionnaire
|
Vaginal swabs are tested on the iStatis Gonorrhea Antigen Test
|
|
Kein Eingriff: Reference Test to evaluate iStatis Performance
Vaginal swabs collected for reference testing will be tested using the Cobas CT/NG reference assay to determine the gonorrhea infection status of participants.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Performance Evaluation
Zeitfenster: 3 months
|
The performance between iStatis Gonorrhea Test and the reference test result for vaginal swabs (operator-collected and self-collected) will be calculated for all sites combined.
Diagnostic sensitivity and specificity values and 95% CIs will be calculated for all subjects combined.
The percentage of invalids (tests that fail to produce a control dot with accurate use) will be identified and reported.
|
3 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
iStatis Gonorrhea Test usability evaluation
Zeitfenster: 3 months
|
Overall test usability and self collection usability will be determined via a questionnaire completed by trained personnel who used the device during testing and study participants that performed sample self-collection respectively.
The usability questionnaire will use a scale of one (1) to 5 (1 - very difficult/very unlikely to 5 - very easy/very likely), with a rating of 3 being satisfactory.
|
3 months
|
|
iStatis Gonorrhea Test contrived result interpretation evaluation
Zeitfenster: 3 months
|
Trained operators will evaluate a panel of contrived (mock) iStatis devices.
These devices are designed to represent a comprehensive range of test outcomes, including strong positives, weak positives, negatives and invalid results.
Operators will interpret the results of the mock devices and record their interpretations which will be compared to the correct interpretation of the device.
|
3 months
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
26. November 2025
Primärer Abschluss (Geschätzt)
1. September 2026
Studienabschluss (Geschätzt)
1. Januar 2027
Studienanmeldedaten
Zuerst eingereicht
21. April 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
29. April 2026
Zuerst gepostet (Tatsächlich)
6. Mai 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
2. Juli 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
30. Juni 2026
Zuletzt verifiziert
1. April 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- CLS-009A
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .